Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1 / Phase 2NCT02805660
Official study title

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Study summary

Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or PD-L1). Durvalumab is also known as a checkpoint inhibitor. This study is evaluating the combination regimen of mocetinostat and durvalumab in participants with Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedMocetinostat - 50 mg and Mocetinostat - 70 mg

Plus 3 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · PD-L1 · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 6, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?15 U.S. locations

Locations may change over time.

Who runs it?Mirati Therapeutics Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
Mirati Therapeutics Inc.
Interventions being studied
Drug: Mocetinostat - 50 mg; Drug: Mocetinostat - 70 mg; Drug: Mocetinostat - 90 mg; Drug: Mocetinostat - Recommended Phase 2 Dose (70 mg); Drug: Durvalumab - 1500 mg
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
Biomarkers
PD-L1→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Phase 1-Diagnosis of advanced or metastatic solid tumor; Phase 2-Diagnosis of NSCLC
  • Not amenable to treatment with curative intent
  • Adequate bone marrow and organ function
Reasons someone may not be able to joinExclusion criteria
  • Impaired heart function
  • Uncontrolled tumor in the brain
  • Other active cancer

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Southern Cancer Center, PCMobile, Alabama
  • David Geffen School of Medicine at UCLALos Angeles, California
  • Woodlands Medical Specialists - PensacolaPensacola, Florida
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern UniversityChicago, Illinois
  • NorthShore University Health SystemEvanston, Illinois
  • Unniversity of Minnesota Masonic Cancer CenterMinneapolis, Minnesota
  • Hackensack University Medical CenterHackensack, New Jersey
  • Montefiore Medical CenterThe Bronx, New York
  • Sarah Cannon Research InstituteNashville, Tennessee
  • Mary Crowley Cancer Research CentersDallas, Texas
  • Texas Oncology - Denton SouthDenton, Texas
  • Texas Oncology-Plano WestPlano, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 6, 2021. Always confirm current availability with the study team.

View original record ↗